- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06310031
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure (INNOVATE)
Investigation of a Novel, magNetically Levitated VAD for the Treatment of refractOry Left Ventricular heArT failurE
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The INNOVATE Trial is a prospective, non-blinded, randomized, controlled, multi-center, non-inferiority study to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3™ (HM3) LVAS (Abbott) when used for the treatment of advanced, refractory left ventricular heart failure. It is the first clinical study to compare two left ventricular assist devices (LVAD) that belong to the same category of fully magnetically levitated LVAD.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham Hospital
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Baptist Health Medical Center-Little Rock
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Florida
-
Gainsville, Florida, United States, 32608
- UF Health Shands Hospital
-
Orlando, Florida, United States, 32803
- Advent Health
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
Atlanta, Georgia, United States, 30309
- Piedmont Healthcare
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Chicago, Illinois, United States, 60453
- Advocate Christ Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Ascension St. Vincent Hospital - Indianapolis
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- The University Of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Medical Center
-
Baltimore, Maryland, United States, 21287
- The Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Detriot, Michigan, United States, 48202
- Henry Ford Health
-
Grand Rapids, Michigan, United States, 49503
- Corewell Health Grand Rapids Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Abbott Northwestern Hospital
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- WashU Medicine
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
New Jersey
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Medical Center
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medicine
-
New York, New York, United States, 10016
- NYU Langone Health
-
New York, New York, United States, 10029
- Mount Sinai
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center/ New York Presbyterian Hospital
-
The Bronx, New York, United States, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital - Cincinnati
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- Baptist - Memphis (Stern)
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor University Medical Center, part of Baylor Scott & White Health
-
Dallas, Texas, United States, 75390
- UT southwestern Medical Center
-
Houston, Texas, United States, 77030
- Houston Methodist Hospital
-
Houston, Texas, United States, 77030
- Memorial Hermann-Texas Medical Center
-
Houston, Texas, United States, 77030
- Texas Heart Institute at Baylor St. Luke's Medical Center
-
Plano, Texas, United States, 75093
- Baylor Scott & White Medical Center - Plano
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Inova Fairfax Medical Campus
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
- Aurora St. Luke's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Patient is ≥ 18 years of age.
-
Patient has received institutional approval for LVAD implantation.
-
Patient has a body surface area (BSA) ≥ 1.2 m2.
-
Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.
-
Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF < 30% on inotropes or temporary MCS.
-
Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters/min/m2, while not on inotropes, and also meets one of the following criteria:
- Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or
- Has advanced heart failure for at least 14 days and is dependent on an intra-aortic balloon pump (IABP) or temporary mechanical circulatory support device (MCSD) for at least seven days.
-
Patient has provided voluntary and informed consent.
-
Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.
Exclusion Criteria:
-
Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis/senile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and/or pericardial disease.
-
Patient had a myocardial infarction within seven days of study enrollment.
-
Patient had cardiothoracic surgery within 30 days of implant with the exception of a procedure to implant temporary MCS: Impella 5.5, Impella CP or TandemHeart.
-
Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.
-
Patient has contraindications to warfarin anticoagulation.
-
Patient has known hypo- or hypercoagulable state [e.g., disseminated intravascular coagulation (DIC)], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.
-
Patient is on durable MCS (e.g., LVAD or RVAD).
-
Planned need for durable or temporary RVAD support concomitant with LVAD implant.
-
Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an intra-aortic balloon pump, Impella 5.5, Impella CP, or TandemHeart.
-
Patient is on any form of pre-implant temporary MCS and has a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or plasma free hemoglobin > 40 g/dL.
-
Patient has a history of organ transplantation.
-
Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.
-
Patient has a platelet count < 50 k/μl.
-
Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter.
-
Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.
-
Patient has an uncontrolled systemic infection.
-
Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin >1000 ug/L.
-
Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:
- Total bilirubin > 3.0 mg/dL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.
- International normalized ratio (INR) ≥ 2.0 or PTT > 2.5 times control that is not related to anticoagulation therapy.
- Glomerular filtration rate (GFR) < 30 mL/ min/1.73 m2 or need for renal replacement therapy.
- Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.
- Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1/FVC < 0.7 and FEV1 < 40% predicted.
- Mechanical ventilation for more than three days present at the time of study enrollment.
- Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.
- History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.
- Symptomatic cerebrovascular disease and/or uncorrected carotid stenosis > 80%.
- Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.
- Pre-albumin < 15 mg/dL and/or albumin < 2.5 g/dL.
-
Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.
-
Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and/or insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.
-
Patient is participating in an interventional clinical trial that may impact or confound the results of the INNOVATE Trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: BrioVAD System
BrioVAD® Left Ventricular Assist System (BrioVAD® System) by BrioHealth Solutions, Inc. |
Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure. |
|
Active Comparator: HeartMate 3
HeartMate 3 System by Abbott |
Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Short-Term Indication Primary Endpoint
Time Frame: 6 months
|
Composite of survival to transplant, recovery or 6 months of LVAD support free of debilitating stroke [modified Rankin Scale (mRS) > 3], or reoperation to replace the pump |
6 months
|
|
Long-Term Indication Primary Endpoint
Time Frame: 24 months
|
Composite of survival to transplant, recovery or 24 months of LVAD support free of debilitating stroke (mRS > 3), or reoperation to replace the pump. |
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Powered Secondary Endpoint
Time Frame: 24 months
|
Total number of nights in hospital, skilled nursing facility, or inpatient rehabilitation, inclusive of index hospitalization, through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. |
24 months
|
|
Short-Term Indication Secondary Endpoint
Time Frame: 6 months
|
Evaluation of the short-term safety using INTERMACS adverse event (AE) terms and definitions through 6 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 6 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. Serious adverse events (SAEs) will be analyzed in a similar manner. |
6 months
|
|
Long-Term Indication Secondary Endpoint
Time Frame: 24 months
|
Evaluation of the long-term safety using INTERMACS AE terms and definitions through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 24 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. SAEs will be analyzed in a similar manner |
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-00545
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Protocol and data is company confidential.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.